HUTCHMED (China) Limited (LSE:HCM) said on 26 October 2026 that detailed SAFFRON data were presented in Presidential Symposium II at the ESMO Congress 2026 in Madrid, as abstract LBA6, on 25 October. The results were simultaneously published in The New England Journal of Medicine.
PureTech Health plc (LSE:PRTC) said on 26 October 2026 that Gallop Oncology, a PureTech Founded Entity that PureTech founded and wholly owns, presented phase 1b results for LYT-200 at the ESMO Congress 2026 in Madrid. The data were presented in an oral session by …
Avacta Group plc (LSE:AVCT), which trades as Avacta Therapeutics, released updated data on 26 October 2026 from its ongoing phase 1a/1b trial of faridoxorubicin (AVA6000) in salivary gland cancer (SGC). The results were presented as poster 1549P at the European Society for Medical Oncology …
HUTCHMED (LSE:HCM) (China) Limited said on 26 October 2026 that full results from SANOVO were presented that morning at 08:30 CET in a Proffered Paper session at the ESMO Congress 2026 in Madrid, as abstract LBA69. The presentation followed the SAFFRON phase III data, …
GSK plc (LSE:GSK) said on 26 October 2026 that ARTEMIS-011, a pivotal phase III, multicentre, randomised, open-label trial in China, met its primary endpoint. The trial tested risvutatug rezetecan, known as Ris-Rez, an investigational antibody-drug conjugate targeting B7-H3, in patients with relapsed or progressed …
GSK plc (LSE:GSK) has released updated results from AZUR-1, a global, open-label, single-arm, registrational phase II trial of Jemperli (dostarlimab) monotherapy in adults with previously untreated stage II and III mismatch repair deficient or microsatellite instability-high (MSI-H/dMMR) locally advanced rectal cancer. The data were …
GSK plc (LSE:GSK) has presented updated data for mocertatug rezetecan, known as Mo-Rez, in patients with platinum-resistant ovarian cancer (PROC). The results were shown in a late-breaking oral session at the ESMO Congress 2026 in Madrid. The release was issued on 23 October 2026 …
On Monday 26 October 2026, Cizzle Biotechnology Holdings plc (LSE:CIZ) (CIZ), whose shares trade on the Main Market of the London Stock Exchange, announced a direct subscription to raise £500,000 before expenses. The release was headlined "£500,000 Subscription, conversion of loan notes". The sole …
The business case for Oxford BioDynamics Plc (LSE:OBD) rests on execution rather than on its market quotation alone. Investors need to distinguish the addressable market from revenue that can realistically be captured, and distinguish an announced opportunity from a signed, profitable contract. Operating leverage …
The business case for Shield Therapeutics Plc (LSE:STX) rests on execution rather than on its market quotation alone. Investors need to distinguish the addressable market from revenue that can realistically be captured, and distinguish an announced opportunity from a signed, profitable contract. Operating leverage …